By Vivek Kalagara, Founder, Datafoundry.ai
The pharmacovigilance outsourcing market is projected to grow from $8.3B to $16.3B. Many see that as a market statistic. But I see it as a warning signal. Because markets don’t double without a structural reason.
For those of us building at the intersection of life sciences and AI, this number is not a surprise. It is a confirmation. But the more important question is why — and what it tells us about where drug safety monitoring is headed.
The Structural Forces Driving This Market
The drivers are interconnected and compounding: more clinical trials, more drug approvals, more complex therapies, and regulatory frameworks that keep raising the bar on accuracy, speed, and audit-readiness.
Oncology alone tells a compelling story. With a 27.5% market share in 2025, it is the largest single therapeutic area driving pharmacovigilance outsourcing. Immunotherapies, targeted therapies, and antibody drug conjugates carry adverse event profiles that require specialised monitoring – not generic safety surveillance. As pipelines grow more complex, the demand for expert partners grows with them.
Small and mid-sized biotechs, in particular, are choosing to outsource not because they want to, but because building equivalent capability in-house is genuinely not feasible at their stage.
Why Outsourcing Has Become Strategic, Not Just Operational
The growth in pharmacovigilance outsourcing is sometimes interpreted as pharmaceutical companies simply trying to cut costs. In my experience, that’s an incomplete picture. The real driver is capability. Today’s safety environment demands:
- Global regulatory expertise across the FDA, EMA, MHRA, and CDSCO
- Scalable operations that flex with trial volumes and approval cycles
- Continuous compliance readiness across evolving submission standards
- Specialised therapeutic knowledge that generalist teams cannot replicate
That said, the market is not without its friction. Regional regulatory differences make standardisation difficult. Data privacy regulations, GDPR and data localisation requirements in particular – add cost and complexity to cross-border safety data sharing. And qualified pharmacovigilance professionals remain in short supply, especially for mid-sized vendors trying to scale without compromising quality.
These are real constraints. But they are also precisely the problems that well-designed technology can help solve.
The AI Opportunity
TMR identifies AI and automation integration as the single biggest opportunity in this market, and I agree. Machine learning and NLP are enabling automatic extraction and categorisation of safety data from unstructured sources. RPA is handling case intake, medical coding, and regulatory submission tracking. AI-powered signal detection is surfacing emerging safety concerns earlier than traditional surveillance methods allow.
I believe that truly touchless case processing, where automation handles everything from intake through medical review, is still more aspiration than reality for most organisations. Having said that, the gap is closing faster than many in the industry acknowledge. The organisations that start building toward that future now, rather than waiting for the technology to mature, will be the ones ahead of the curve five years from now.
Recent Moves Worth Watching
On June 3, 2026, the DCGI issued a circular directing all drug manufacturers and importers to establish full pharmacovigilance systems under the revised Schedule M norms that came into force on January 1 this year. Every licensee now needs a Pharmacovigilance System Master File, a qualified PV officer-in-charge, and a functioning ADR collection, processing, and reporting system – verified during routine inspections, no exceptions.
Industry observers note that large companies largely have this in place. The circular is aimed squarely at the hundreds of mid-sized and smaller manufacturers who have historically operated without structured pharmacovigilance infrastructure. The DCGI has been unambiguous: no further extensions.
This is, by some accounts, the most extensive regulatory shift in Indian pharma in forty years. For a sector that supplies a significant share of the world’s generic medicines, this is not administrative housekeeping, it is a fundamental repositioning of how drug safety is monitored in India. And it creates an urgent, real-world demand for pharmacovigilance infrastructure that can be deployed quickly, cost-effectively, and at scale.
What Datafoundry Brings to This Moment
This is precisely the challenge we have spent years preparing for at Datafoundry.ai
Our platform, DF Safety AI, is purpose-built for end-to-end pharmacovigilance not adapted from a generic data management system, not assembled from point solutions, but designed from the ground up to address the full spectrum of safety vigilance challenges that pharmaceutical companies, CROs, and medical device manufacturers face today. From automated case intake and triage through medical review, signal detection, literature monitoring, and E2B R2/R3-compliant regulatory submission, the architecture is integrated and AI-native.
A few things that distinguish our approach:
- Multi-Vigilance architecture : a single platform spanning drugs, cosmetics, medical devices, and vaccines, rather than four separate systems with four separate maintenance burdens
- Explainable AI : signal detection that tells you not just what was flagged, but why, traceable to GVP Module IX expectations
- 60% reduction in implementation time compared to traditional safety platforms : critical for organisations that need to be compliant now, not in eighteen months
For Indian manufacturers navigating Schedule M compliance, for biotechs scaling their post-marketing obligations, and for CROs managing safety across a growing global client base – the question is no longer whether to invest in AI-driven pharmacovigilance. It is how fast you can move.
The Conversation the Industry Needs to Have
Pharmacovigilance is no longer just becoming digital. It is becoming intelligent. The companies that recognise the difference today will define drug safety tomorrow.
Source: Market data and insights cited in this article are drawn from Transparency Market Research’s “Pharmacovigilance Outsourcing Market Outlook 2036” report.
Vivek Kalagara is the Founder of Datafoundry, an AI platform for pharmacovigilance, drug safety, and safety vigilance across life sciences. Datafoundry’s solutions serve pharmaceutical companies, CROs, medical device manufacturers, and cosmetics brands globally. Learn more at datafoundry.ai